The Cocktail Report (sound really smart around your friends):
Berkeley researchers gave semaglutide, the drug in Ozempic and Wegovy, to old female mice and let them live out their lives.
Median lifespan rose from 742 days on placebo to 834 days on semaglutide, an increase of about 12 percent.
A parallel arm compared semaglutide directly to matched calorie restriction, the only intervention proven to extend lifespan across species.
Semaglutide matched most benefits of calorie restriction and beat it on exploratory drive, spatial memory, and glucose control.
This is mouse data, published this month in Nature, and no human lifespan trial exists.
Everyone in your circle already asks about Ozempic. This week the conversation about it shifted, because Nature published the first study to show a GLP-1 drug extending lifespan in mammals.
The team was led by Danica Chen at UC Berkeley, with collaborators at the National Institute on Aging and the University of Copenhagen. The paper appeared September 2 in Nature.
The researchers started with 20-month-old female C57BL/6 mice, roughly equivalent to a 65-year-old woman. That timing matters, because most longevity interventions in mice start in youth.
One group received semaglutide by subcutaneous injection for the rest of their lives. Median lifespan rose from 742 days in controls to 834 days on semaglutide.
That is about a 12 percent extension, starting the drug in late middle age. Older mice on semaglutide also stayed more physically and mentally active than controls.
A second cohort was treated for three months and then examined in detail. Semaglutide-treated mice moved more, explored more in open-field tests, and showed better memory and coordination.
Semaglutide also revived neurogenesis in the hippocampus, the brain region where new neurons form throughout life and where aging normally shuts that process down. On paper, this is what a calorie-restriction mimetic should look like.
That comparison is where the study goes further than anything before it. The researchers ran a parallel arm of matched calorie restriction and directly compared the two.
Semaglutide reduced food intake by 24 percent, so the drug is partly working through eating less. But head-to-head, semaglutide beat calorie restriction on exploratory drive, on spatial memory, and on glucose control.
The two interventions engaged overlapping aging pathways, but with distinct signatures. That is an important nuance for anyone assuming the drug is just injected fasting.
A word of caution. This trial used only female mice, of one strain, at one facility.
Male mice were not tested. Human lifespan data does not exist and is not coming soon.
Set against those limits, the finding is still meaningful. Late-life intervention rarely extends lifespan in mice, and matching calorie restriction is a high bar.
If you take a GLP-1 drug for weight or diabetes, do not change your dose based on this. If you avoid the drug because you consider it a cosmetic weight tool, this data suggests there is more going on inside.
Why Should You Care?
Millions of people are already taking semaglutide for weight or diabetes. This is the first hard evidence in a mammal that the drug may also be reaching into the machinery of aging itself.
1. Feng Y, Barthez M, Wang Y, et al. Late-life semaglutide treatment slows ageing and extends lifespan in female mice. Nature. 2026 Sep;657(8131):469-476. DOI: 10.1038/s41586-026-10940-7. PMID 42686906. Free full text at https://pmc.ncbi.nlm.nih.gov/articles/PMC13558073/
2. Scientists find Ozempic may slow aging itself. ScienceDaily, September 12, 2026. https://www.sciencedaily.com/releases/2026/09/260911214238.htm
3. GLP-1 treatment late in life extends lifespan in animal model. Medical Xpress, September 2, 2026. https://medicalxpress.com/news/2026-09-glp-treatment-late-life-lifespan.html
